
ORR of 25.6%, yet an exceptional median PFS of 22.1 months! Final phase II PECATI results suggest that lenvatinib + pembrolizumab may provide prolonged disease stabilisation beyond objective responses in pretreated advanced thymic tumours @JTOonline Congrats to @JordiRemon & colleagues! @IASLC doi.org/10.1016/j.jtho.2026.…
































